188 related articles for article (PubMed ID: 28454883)
1. Treatment of inflammatory bowel disease by leukocytapheresis.
Gerçeker E; Yüceyar H; Kasap E; Demirci U; Ekti BC; Aydoğdu İ; Miskioğlu M
Transfus Apher Sci; 2017 Jun; 56(3):421-426. PubMed ID: 28454883
[TBL] [Abstract][Full Text] [Related]
2. A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: treatment outcomes of 847 patients in clinical practice.
Yokoyama Y; Matsuoka K; Kobayashi T; Sawada K; Fujiyoshi T; Ando T; Ohnishi Y; Ishida T; Oka M; Yamada M; Nakamura T; Ino T; Numata T; Aoki H; Sakou J; Kusada M; Maekawa T; Hibi T
J Crohns Colitis; 2014 Sep; 8(9):981-91. PubMed ID: 24556083
[TBL] [Abstract][Full Text] [Related]
3. Role of leukocytapheresis in the management of inflammatory bowel disease.
Fukunaga K; Miwa H; Matsumoto T
Trop Gastroenterol; 2007; 28(1):11-5. PubMed ID: 17896603
[TBL] [Abstract][Full Text] [Related]
4. Recent understanding of leukocytapheresis (LCAP) for the treatment of inflammatory bowel disease.
Mitsuyama K; Yamasaki H; Kuwaki K; Takedatsu H; Sata M
Curr Pharm Des; 2009; 15(18):2110-9. PubMed ID: 19519448
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action.
Mitsuyama K; Sata M
Cytotherapy; 2009; 11(2):229-37. PubMed ID: 19241197
[TBL] [Abstract][Full Text] [Related]
6. Leukocytapheresis is effective in inducing but not in maintaining remission in ulcerative colitis.
Honma T; Sugimura K; Asakura H; Matsuzawa J; Suzuki K; Kobayashi M; Aoyagi Y
J Clin Gastroenterol; 2005; 39(10):886-90. PubMed ID: 16208112
[TBL] [Abstract][Full Text] [Related]
7. New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease.
Kawamura A; Saitoh M; Yonekawa M; Horie T; Ohizumi H; Tamaki T; Kukita K; Meguro J
Ther Apher; 1999 Nov; 3(4):334-7. PubMed ID: 10608731
[TBL] [Abstract][Full Text] [Related]
8. [Granulocytapheresis in inflammatory bowel disease. Efficacy of an induction plus maintenance sessions protocol at 32 weeks].
Fernández Pérez FJ; Rodríguez F; de Sola C; Fernández Moreno N; Vera F; Rivera R; Sánchez Cantos A
Rev Esp Enferm Dig; 2007 Nov; 99(11):628-35. PubMed ID: 18271660
[TBL] [Abstract][Full Text] [Related]
9. Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease.
Sawada K
Dis Colon Rectum; 2003 Oct; 46(10 Suppl):S66-77. PubMed ID: 14530661
[TBL] [Abstract][Full Text] [Related]
10. Current status and future perspectives of leukocytapheresis for inflammatory bowel disease.
Fukunaga K; Matsumoto T
J Gastroenterol Hepatol; 2012 Jun; 27(6):997-1003. PubMed ID: 22414250
[TBL] [Abstract][Full Text] [Related]
11. Steroid-sparing strategies in the management of ulcerative colitis: efficacy of leukocytapheresis.
Shiraki M; Yamamoto T
World J Gastroenterol; 2012 Nov; 18(41):5833-8. PubMed ID: 23139598
[TBL] [Abstract][Full Text] [Related]
12. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial.
Emmrich J; Petermann S; Nowak D; Beutner I; Brock P; Klingel R; Mausfeld-Lafdhiya P; Liebe S; Ramlow W
Dig Dis Sci; 2007 Sep; 52(9):2044-53. PubMed ID: 17410456
[TBL] [Abstract][Full Text] [Related]
13. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease.
Kanai T; Hibi T; Watanabe M
Expert Opin Biol Ther; 2006 May; 6(5):453-66. PubMed ID: 16610976
[TBL] [Abstract][Full Text] [Related]
14. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease.
Sawada K; Ohnishi K; Fukui S; Yamada K; Yamamura M; Amano K; Amano K; Wada M; Tanida N; Satomi M
J Gastroenterol; 1995 Jun; 30(3):322-9. PubMed ID: 7647899
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis.
Zhu M; Xu X; Nie F; Tong J; Xiao S; Ran Z
Int J Colorectal Dis; 2011 Aug; 26(8):999-1007. PubMed ID: 21476027
[TBL] [Abstract][Full Text] [Related]
16. Leukocytapheresis in the treatment of inflammatory bowel disease: Current position and perspectives.
Vernia P; D'Ovidio V; Meo D
Transfus Apher Sci; 2010 Oct; 43(2):227-9. PubMed ID: 20817610
[TBL] [Abstract][Full Text] [Related]
17. Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease.
Sawada K; Ohnishi K; Kosaka T; Fukui S; Yamamura M; Amano K; Satomi M; Shimoyama T
J Gastroenterol; 1995 Nov; 30 Suppl 8():124-7. PubMed ID: 8563873
[TBL] [Abstract][Full Text] [Related]
18. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
[TBL] [Abstract][Full Text] [Related]
19. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
20. Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease.
Sáez-González E; Moret I; Alvarez-Sotomayor D; Díaz-Jaime FC; Cerrillo E; Iborra M; Nos P; Beltrán B
Dig Dis Sci; 2017 Jun; 62(6):1417-1425. PubMed ID: 28432476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
